Biotechnology development (+CILS)

Monday April 23: 8.30 – 10:00 + 10.30 – 12:00; Tuesday April 24: 8.30 – 10:00 + 10.30 – 11:15 + 13:30 – 15:15 Monday April 30: 8.30 – 10:00 + 10:30-12:00 + 13.30 – 15:00; Wednesday May 2: 14.30 – 16:00; Monday May 7: 09:00 – 12:00

Dr Marie KOSCO-VILLEBOIS (CSO, NovImmune )

collaborateurs de NovImmune

Course Outline:

· - Overview of the steps for drug development (2h)

· - Choosing and validating a protein as a target for pharmaceutical intervention (2h)

· - Discovering a therapeutic macromolecule with an emphasis on antibodies (monoclonal, bispecific, fragments) (2h)

· - Generating a robust toolbox and screening approaches (1h)

· - Steps in manufacturing antibodies (1h)

· - Manufacturing a drug for market: process validation (1h)

· - In vitro and in vivo pharmacology studies (2h)

· - Testing samples from clinical trials and the notion of GCP (2h)

· - Nonclinical safety: toxicology and other safety considerations before entering humans (2h)

· - Awaking the immune system to fight cancer by targeting CD47 (2h)

· - Targeting chemokines: successes and failures (1h)

· - Targeting rare diseases: The orphan story (2h)

UNIGE, CMU room A04.2706, room A04.2910 on May 7

10